Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CASP6 | P55212 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11463578 | 0.89 | ALDH1A1 (0.48) | CA12CA1CA2CA7CA9 | |
| SCHEMBL11455556 | 0.88 | ALDH1A1 (0.47) | CA12CA1CA2CA7CA9 | |
| SCHEMBL11539257 | 0.84 | LMNA (0.48) | GPR35ALDH1A1L3MBTL1MAPTGAA | |
| SCHEMBL11540199 | 0.84 | IRAK4 (0.48) | CA1CA2CA7CA9GPR35 | |
| SCHEMBL11541411 | 0.84 | CA12 (0.49) | CA12CA1CA2CA7CA9 | |
| SCHEMBL11537144 | 0.82 | MAPT (0.50) | GPR35ALDH1A1SMN1; SMN2RAB9AMAPT | |
| SCHEMBL11455504 | 0.82 | ALDH1A1 (0.45) | CA12CA1CA2CA7CA9 | |
| SCHEMBL11445340 | 0.82 | GPR35 (0.58) | GPR35ALDH1A1SMN1; SMN2RAB9AL3MBTL1 | |
| SCHEMBL11540031 | 0.81 | KMT2A (0.47) | GPR35ALDH1A1RAB9AL3MBTL1MAPT | |
| SCHEMBL4722310 | 0.81 | LMNA (0.55) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4154961-A | Oxamic acid derivatives | AMERICAN HOME PRODUCTS CORPORATION (US) | 1979-05-15 | — | — | US | claimed |
| US-4069343-A | OXAMIC ACID DERIVATIVES FOR THE PREVENTION OF IMMEDIATE TYPE HYPERSENSITIVITY REACTIONS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1978-01-17 | — | — | US | claimed |
| US-9475822-B2 | Substituted 2- amidoquinazol-4-ones as matrix metalloproteinase-13 inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-10-25 | — | — | US | disclosed |
| US-9212149-B2 | Substituted 2-amidoquinazol-4-ones as matrix metalloproteinase-13 inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-12-15 | — | — | US | disclosed |
| US-20150329556-A1 | SUBSTITUTED 2- AMIDOQUINAZOL-4-ONES AS MATRIX METALLOPROTEINASE-13 INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2015-11-19 | — | — | US | disclosed |
| EP-1740551-B9 | HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF AS AN MMP-13 INHIBITOR | TAKEDA PHARMACEUTICAL (JP) | 2013-01-16 | — | — | EP | disclosed |
| EP-1740551-B1 | HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF AS AN MMP-13 INHIBITOR | TAKEDA PHARMACEUTICAL (JP) | 2012-09-12 | — | — | EP | disclosed |
| US-20080027050-A1 | Heterocyclic Amide Compound and Use Thereof as an Mmp-13 Inhibitor(Amended Ex Officio) | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-31 | — | — | US | disclosed |
| US-4191840-A | Oxamic acid derivatives | AMERICAN HOME PRODUCTS CORPORATION (US) | 1980-03-04 | — | — | US | disclosed |
| US-4181761-A | Shaped articles of ethylene-vinyl acetate copolymer having a coating of NCO-free radical-containing synthetic resin paint | MITSUI POLYCHEMICALS CO., LTD. (JP) | 1980-01-01 | — | — | US | disclosed |
| US-4160100-A | OXAMIC ACID DERIVATIVES | AMERICAN HOME PRODUCTS CORPORATION (US) | 1979-07-03 | — | — | US | disclosed |
| US-4154961-A | Oxamic acid derivatives | AMERICAN HOME PRODUCTS CORPORATION (US) | 1979-05-15 | — | — | US | disclosed |
| US-4069343-A | OXAMIC ACID DERIVATIVES FOR THE PREVENTION OF IMMEDIATE TYPE HYPERSENSITIVITY REACTIONS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1978-01-17 | — | — | US | disclosed |
| US-4054661-A | Pyridyl oxamic acid derivatives and use in the prevention of allergic reactions | AMERICAN HOME PRODUCTS CORPORATION (US) | 1977-10-18 | — | — | US | disclosed |
| US-4054666-A | Compositions and methods of treating immediate hypersensitivity reactions with thiazolyl oxamic acid derivatives | AMERICAN HOME PRODUCTS CORPORATION (US) | 1977-10-18 | — | — | US | disclosed |
| US-4054657-A | Pyrimidinyl oxamic acids and esters, and compositions and methods for the suppression of allergic manifestations | AMERICAN HOME PRODUCTS CORPORATION (US) | 1977-10-18 | — | — | US | disclosed |
| US-4036837-A | 2 Alkoxyoxamoyl-pyrazines | AMERICAN HOME PRODUCTS CORPORATION (US) | 1977-07-19 | — | — | US | disclosed |
| US-3966965-A | Oxamic acid derivatives for the prevention of immediate type hypersensitivity reactions | AMERICAN HOME PRODUCTS CORPORATION (US) | 1976-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150329556-A1 | SUBSTITUTED 2- AMIDOQUINAZOL-4-ONES AS MATRIX METALLOPROTEINASE-13 INHIBITORS | MMP13, MMP14, MMP25 | CA12 960/4885CA1 248/4885CA2 487/4885 |
| US-20080027050-A1 | Heterocyclic Amide Compound and Use Thereof as an Mmp-13 Inhibitor(Amended Ex Officio) | MMP13, HDAC11, HDAC1 | CA12 712/4885CA1 484/4885CA2 893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.